Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 23;326(11):1063-1065.
doi: 10.1001/jama.2021.12339. Online ahead of print.

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Affiliations

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Ilies Benotmane et al. JAMA. .

Abstract

This study examines the antibody responses to a third dose (100 μg) of the mRNA-1273 SARS-CoV-2 vaccine among kidney transplant recipients in France who had not responded to 2 doses of the vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Caillard reported receiving travel grants from Astellas, Novartis, and Sanofi and receiving lecture honoraria from Bristol Myers Squibb. Dr Benotmane reported receiving travel grants from Novartis, Sandoz, Fresenius Medical Care, and Chiesi. No other disclosures were reported.

Figures

Figure.
Figure.. Anti–Receptor-Binding Domain (RBG) IgG Antibody Titers Measured 28 Days After the Third Dose of mRNA-1273 SARS-CoV-2 Vaccine in 159 Kidney Transplant Recipients
Horizontal dotted line indicates the cutoff for positivity (50 arbitrary units [AU]/mL). Blue lines indicate the antibody titers of kidney transplant recipients who seroconverted after the third dose (titers ≥50 AU/mL); orange lines, the evolution of antibody titers among nonresponders (titers <50 AU/mL). mRNA indicates messenger RNA.

Similar articles

Cited by

References

    1. Boyarsky BJ, Werbel WA, Avery RK, et al. . Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021;325(17):1784-1786. doi:10.1001/jama.2021.4385 - DOI - PMC - PubMed
    1. Boyarsky BJ, Werbel WA, Avery RK, et al. . Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204-2206. doi:10.1001/jama.2021.7489 - DOI - PMC - PubMed
    1. Prendecki M, Clarke C, Brown J, et al. . Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397(10280):1178-1181. doi:10.1016/S0140-6736(21)00502-X - DOI - PMC - PubMed
    1. Werbel WA, Boyarsky BJ, Ou MT, et al. . Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med. Published online June 15, 2021. doi:10.7326/L21-0282 - DOI - PMC - PubMed
    1. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. Published online June 23, 2021. doi:10.1056/NEJMc2108861 - DOI - PMC - PubMed